Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:T2-high asthma, classified by sputum mRNA expression of IL4, IL5, and IL13, is characterized by eosinophilia and severe phenotype
Authors:ID Rijavec, Matija, Klinika Golnik, Biotehniška fakulteta UL (Author)
ID Krumpestar, Tomaž, Klinika Golnik (Author)
ID Škrgat, Sabina, Klinika Golnik, Medicinska fakulteta UL, Univerzitetni klinični center Ljubljana (Author)
ID Kern, Izidor, Klinika Golnik (Author)
ID Korošec, Peter, Klinika Golnik (Author)
Files:.pdf PDF - Presentation file, download (1,31 MB)
MD5: E6C630E451F9E0DB5B885A8A25B633A4
 
URL URL - Source URL, visit https://www.mdpi.com/2075-1729/11/2/92/pdf
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
Abstract:Asthma is a common chronic disease, with different underlying inflammatory mechanisms. Identification of asthma endotypes, which reflect a variable response to different treatments, is important for more precise asthma management. T2 asthma is characterized by airway inflammation driven by T2 cytokines including interleukins IL-4, IL-5, and IL-13. This study aimed to determine whether induced sputum samples can be used for gene expression profiling of T2-high asthma classified by IL4, IL5, and IL13 expression. Induced sputum samples were obtained from 44 subjects, among them 36 asthmatic patients and eight controls, and mRNA expression levels of IL4, IL5, and IL13 were quantified by RT-qPCR. Overall, gene expression levels of IL4, IL5, and IL13 were significantly increased in asthmatic patients' samples compared to controls and there was a high positive correlation between expressions of all three genes. T2 gene mean was calculated by combining the expression levels of all three genes (IL4, IL5, and IL13) and according to T2 gene mean expression in controls, we set a T2-high/T2-low cutoff value. Twenty-four (67%) asthmatic patients had T2-high endotype and those patients had significantly higher eosinophil blood and sputum counts. Furthermore, T2-high endotype was characterized as a more severe, difficult-to-treat asthma, and often uncontrolled despite the use of inhaled and/or oral corticosteroids. Therefore, the majority of those patients (15 [63%] of 24) needed adjunct biological therapy to control their asthma symptoms/exacerbations. In conclusion, we found that interleukins IL4, IL5, and IL13 transcripts could be effectively detected in sputum from asthmatic patients. Implementation of T2 gene mean can be used as sputum molecular biomarker to categorize patients into T2-high endotype, characterized by eosinophilia and severe, difficult-to-treat asthma, and often with a need for biological treatment.
Keywords:asthma, gene expression, interleukin-4, interleukin-5, interleukin-13, severe asthma, endotype, IL-4, IL-5, IL-13, biologic treatment
Publication status:Published
Publication version:Version of Record
Place of publishing:Švica
Publisher:MDPI
Year of publishing:2021
Number of pages:str. 1-10
Numbering:Vol. 1, iss. 2
PID:20.500.12556/DiRROS-13699 New window
UDC:616-097
ISSN on article:2075-1729
DOI:10.3390/life11020092 New window
COBISS.SI-ID:49321987 New window
Copyright:© 2021 by the authors.
Note:Nasl. z nasl. zaslona; Soavtorji: Tomaž Krumpestar, Sabina Škrgat, Izidor Kern, Peter Korošec; Opis vira z dne 29. 1. 2021; Št. članka: 92;
Publication date in DiRROS:02.02.2021
Views:1725
Downloads:1095
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Life
Shortened title:Life
Publisher:MDPI
ISSN:2075-1729
COBISS.SI-ID:519982617 New window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:27.01.2021

Secondary language

Language:Undetermined
Keywords:astma, gensko izražanje, interlevkin-4, interlevkin-5, interlevkin-13, težka astma, endotip, IL-4, IL-5, IL-13, biološko zdravljenje


Back